<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870359</url>
  </required_header>
  <id_info>
    <org_study_id>UW-16-074</org_study_id>
    <nct_id>NCT04870359</nct_id>
  </id_info>
  <brief_title>Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation</brief_title>
  <official_title>Pre-emptive Increase of Immunosuppressive Treatments in Lupus Nephritis Patients With Asymptomatic Serological Reactivation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN)&#xD;
      patients remained undefined. This project aims to investigate the impact of pre-emptive&#xD;
      treatment on disease relapse in LN patients who experienced ASR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LN patients who presented with ASR [defined as 1) increase in anti-dsDNA &gt;100 IU/mL , with or&#xD;
      without drop in serum complement; or 2) increase in anti-dsDNA to higher than the normal&#xD;
      range and &gt;2 times of the preceding value, with or without drop in serum complement; and 3)&#xD;
      Absence of renal or systemic manifestations of SLE) will be randomized to receive pre-emptive&#xD;
      increase in immunosuppression or had their current immunosuppressive therapies unchanged.&#xD;
&#xD;
      Patients will be followed at 4-, 12-, 24-wk and then every 12 weeks up to 24 months to&#xD;
      monitor for renal or extra-renal relapses. Bloods and urine will be collected for measurement&#xD;
      of renal and serological parameters, and also B cell signatures.&#xD;
&#xD;
      Primary outcomes: Renal Flare (denoted as proteinuria &gt;1g/D; presence of urinary RBC &gt;30&#xD;
      hpf/RBC casts, or increase in SCr &gt;15% and positive anti-dsDNA)&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  Safety &amp; tolerability of pre-emptive increase of immunosuppressive treatments&#xD;
&#xD;
        -  Extra-renal flares&#xD;
&#xD;
        -  Renal function at 24 months&#xD;
&#xD;
        -  Changes in serological parameters&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Flare</measure>
    <time_frame>Within 24 months</time_frame>
    <description>A composite endpoint denoted by proteinuria &gt;1g/day, presence of urinary RBC &gt;30/hpf or RBC casts, or increase in serum creatinine by 15% compared with baseline, and anti-DNA antibody titre above the upper limit of normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infections requiring hospitalization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-renal flares</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine levels</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anti-dsDNA</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in C3</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hba1c</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL levels</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Pre-emptive Treatment (Prednisolone and/or AZA/MMF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.&#xD;
Adjustment of the 2nd agent would be as follows:&#xD;
For patients who receive AZA &lt;75mg/day; increase the dose of AZA to 75 mg/day.&#xD;
For patients who receive MMF &lt;1g/day, increase the dose of MMF to 1g/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current immunosuppressive regimen and dosage should remain unchanged until the development of renal or extra-renal flares which required increase/change in immunosuppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre-emptive increase of immunosuppressive treatments</intervention_name>
    <description>Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.&#xD;
Adjustment of the 2nd agent would be as follows:&#xD;
For patients who receive AZA &lt;75mg/day; increase the dose of AZA to 75 mg/day.&#xD;
For patients who receive MMF &lt;1g/day, increase the dose of MMF to 1g/day.</description>
    <arm_group_label>Pre-emptive Treatment (Prednisolone and/or AZA/MMF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone and/or AZA/MMF</intervention_name>
    <description>Prednisolone and/or AZA/MMF</description>
    <arm_group_label>Pre-emptive Treatment (Prednisolone and/or AZA/MMF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy-proven lupus nephritis who experienced an episode of Asymptomatic&#xD;
             Serological Flare (ASF) as defined by:&#xD;
&#xD;
               1. Increase in anti-dsDNA to &gt;100 IU/mL, with or without drop in serum complement&#xD;
                  levels OR&#xD;
&#xD;
               2. Increase in anti-dsDNA to higher than the normal range and more than two times of&#xD;
                  the preceding value, with or without drop in serum complement levels&#xD;
&#xD;
                  AND&#xD;
&#xD;
               3. Absence of renal or systemic manifestation of SLE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who cannot provide informed consent.&#xD;
&#xD;
          2. Patients whom the clinicians opined to have excessively high risk of infection or&#xD;
             malignancy.&#xD;
&#xD;
          3. Patients who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Desmond YH Yap, MBBS (HK). MD (HK)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Desmond YH YAP, MBBS (HK), MD (HK)</last_name>
    <phone>85222554385</phone>
    <email>desmondy@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital, Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desmond Yap, MD</last_name>
      <phone>85222553879</phone>
      <email>desmondy@hku.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United Christian Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Tam</last_name>
      <phone>85235176677</phone>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

